Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
This 2 part series, presented in Spanish for the Latino community, covers information relating to the following topics. Please scroll down for part 2 of this important series.
What is coronavirus?
¿Qué es el COVID-19?
What are the common symptoms?
¿Cuales son los síntomas mas comunes de la infección COVID-19?
How is it contracted, and how can it be prevented?
¿Qué puedo hacer para evitar contraer COVID-19?
Who is at risk, and are people with cancer at higher risk?
¿Las personas con cáncer deberían tomar precauciones especiales?
Does the risk of exposure change my treatment for cancer?
¿Puede el riesgo de exposición al virus cambiar mi tratamiento para el cáncer? ¿Como va a cambiar mi interacción con mi doctor del cáncer?
What happens if I get coronavirus and have cancer?
¿Que pasa si me contraigo el coronavirus?
¿Puedo seguir con mi tratamiento para el cáncer?
I hear about treatments: are these now established as effective?
¿Hay tratamientos para COVID-19?
¿Puede la inmunoterapia protegerme en contra del COVID-19?
For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Please feel free to offer comments and raise questions in our
discussion forums.
Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...
The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)
There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...
Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.
The...
Biomarkers are genetic mutations (like EGFR, ALK, KRAS, BRAF) or protein levels (like PD-L1) in tumor cells that help guide personalized treatment, especially NSCLC, directing patients to targeted therapies or immunotherapies...
Hi Stan! So good to hear from you. I'm sorry for the late response. I too have been out of town with family and missed your post, probably because I was...
It is so good to hear from you! And I am so happy to hear that your holidays have been good and that you are doing well. It sounds like your...
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components: